

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>EuclidSR Partners, L.P.</u> (Last) (First) (Middle) 45 ROCKEFELLER PLAZA, SUITE 1410 (Street) NEW YORK NY 10111 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>FLUIDIGM CORP [FLDM]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/15/2011	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/15/2011	02/15/2011	C ⁽¹⁾		47,400	A	(2)	47,400	I	See Footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/15/2011	02/15/2011	C ⁽⁵⁾		320,063	A	(2)	367,463	I	See Footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/15/2011	02/15/2011	C ⁽⁵⁾		66,991	A	(2)	434,454	I	See Footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/15/2011	02/15/2011	C ⁽¹⁾		47,400	A	(2)	481,854	I	See Footnotes ⁽⁴⁾⁽⁶⁾
Common Stock	02/15/2011	02/15/2011	C ⁽⁵⁾		320,063	A	(2)	801,917	I	See Footnotes ⁽⁴⁾⁽⁶⁾
Common Stock	02/15/2011	02/15/2011	C ⁽⁵⁾		66,991	A	(2)	868,908	I	See Footnotes ⁽⁴⁾⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series E Preferred Stock	(2)	02/15/2011	02/15/2011	C			47,400	(7)	(7)	Common Stock	47,400	\$0	821,508	I	See Footnotes ⁽³⁾⁽⁴⁾
Series C Preferred Stock	(2)	02/15/2011	02/15/2011	C			320,063	(8)	(8)	Common Stock	320,063	\$0	501,445	I	See Footnotes ⁽³⁾⁽⁴⁾
Series D Preferred Stock	(2)	02/15/2011	02/15/2011	C			66,991	(8)	(8)	Common Stock	66,991	\$0	434,454	I	See Footnotes ⁽³⁾⁽⁴⁾
Series E Preferred Stock	(2)	02/15/2011	02/15/2011	C			47,400	(7)	(7)	Common Stock	47,400	\$0	387,054	I	See Footnotes ⁽⁴⁾⁽⁶⁾
Series C Preferred Stock	(2)	02/15/2011	02/15/2011	C			320,063	(8)	(8)	Common Stock	320,063	\$0	66,991	I	See Footnotes ⁽⁴⁾⁽⁶⁾
Series D Preferred Stock	(2)	02/15/2011	02/15/2011	C			66,991	(8)	(8)	Common Stock	66,991	\$0	0	I	See Footnotes ⁽⁴⁾⁽⁶⁾

1. Name and Address of Reporting Person*
EuclidSR Partners, L.P.

 (Last) (First) (Middle)
 45 ROCKEFELLER PLAZA, SUITE 1410

 (Street)

NEW YORK NY 10111

(City) (State) (Zip)

1. Name and Address of Reporting Person*

EuclidSR Biotechnology Partners, L.P.

(Last) (First) (Middle)

45 ROCKEFELLER PLAZA, SUITE 1410

(Street)
NEW YORK NY 10111

(City) (State) (Zip)

Explanation of Responses:

1. Represents shares of Common Stock issued upon conversion of shares of Series E Preferred Stock on a 1-for-1.300053676865 basis.
2. Not applicable.
3. EuclidSR Partners, L.P., is the record holder of the securities reported.
4. These securities are owned of record by EuclidSR Partners, L.P., for which voting and investment power is shared by Graham D.S. Anderson, Milton J. Pappas, Stephen K. Reidy and Raymond J. Whitaker, each of whom is a general partner of EuclidSR Associates, L.P., the general partner of EuclidSR Partners, L.P. Raymond J. Whitaker, a member of the Board of Directors of the Issuer, and each of the other general partners of EuclidSR Associates, L.P. disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
5. Represents shares of Common Stock issued upon the conversion of shares of Series C Preferred Stock or Series D Preferred Stock on a 1-for-1 basis.
6. EuclidSR Biotechnology Partners, L.P. is the record holder of the securities reported.
7. Each share of Series E Preferred Stock automatically converted into 1.300053676865 share of Common Stock on February 15, 2011, the closing date of the Issuer's initial public offer (the "Closing") and has no expiration date.
8. Each share of Series C Preferred Stock or Series D Preferred Stock automatically converted into one share of Common Stock on the Closing and has no expiration date.

/s/ William Smith, attorney-in-
fact 02/16/2011

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.